Amgen snaps up Alantos in buying spree

Amgen scored its second sizeable acquisition in two days with its announcement that it will pay $300 million for Alantos Pharmaceuticals. Cambridge, MA-based Alantos' lead drug candidate--ALS 2-0426--is a DPP-IV inhibitor in Phase IIa, a popular approach to treating Type 2 diabetes. Servient is the development partner on the program. An acquisition-hungry Amgen snapped up Ilypsa yesterday for $420 as it takes out its check book to buy up new drug candidates.

"We also intend to pursue the MMP program with the hope of bringing a novel, disease modifying therapy into the clinic for osteoarthritis," said Roger M. Perlmutter, M.D., Ph.D., Amgen's executive vice president for research and development.

- check out the release on the deal

Related Articles:
Amgen in crisis? Not us, says CEO Sharer. Report
Major challenges loom for Amgen. Report
Amgen CFO walks as challenges mount. Report

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.